Coherus Oncology (CHRS) Net Cash Flow (2013 - 2026)
Coherus Oncology (CHRS) reported Net Cash Flow of $26.4 million for Q1 2026, up 160.49% on a YoY basis from $10.1 million in Q1 2025, and up 282.13% sequentially from -$14.5 million in Q4 2025.
Coherus Oncology (CHRS) Net Cash Flow (2013 - 2026) Analysis & Trends
Coherus Oncology (CHRS) has 14 years of Net Cash Flow data on file, last reported at $26.4 million in Q1 2026.
- For the quarter ending Q1 2026, Net Cash Flow rose 160.49% year-over-year to $26.4 million; the trailing twelve-month figure through Mar 2026 stood at $32.8 million (up 118.48% YoY), and the FY2025 full-year result was -$37.1 million, down 262.09% from the prior year.
- Net Cash Flow rose to $26.4 million in Q1 2026, from -$14.5 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $156.9 million in Q1 2024 to a low of -$223.3 million in Q4 2022.
- A 5-year average of -$17.8 million and a median of -$14.5 million in 2025 frame the typical range for Net Cash Flow.
- Peak annual rise in Net Cash Flow reached 430.96% in 2024, while the deepest fall reached 939.87% in 2024.
- Tracing CHRS's Net Cash Flow over 5 years: stood at -$223.3 million in 2022, then soared by 110.14% to $22.6 million in 2023, then gained by 25.03% to $28.3 million in 2024, then tumbled by 151.15% to -$14.5 million in 2025, then soared by 282.13% to $26.4 million in 2026.
- Business Quant data shows CHRS's Net Cash Flow at $26.4 million in Q1 2026, -$14.5 million in Q4 2025, and -$113.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Coherus Oncology | 195.05 Mn | 28.00 Mn | 8.50 Mn | 26.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.36 Mn |
| Mar 31, 2026 | 26.36 Mn |
| Dec 31, 2025 | -14.47 Mn |
| Dec 31, 2025 | -14.47 Mn |
| Sep 30, 2025 | -113.56 Mn |
| Sep 30, 2025 | -113.56 Mn |
| Jun 30, 2025 | 134.48 Mn |
| Jun 30, 2025 | 134.48 Mn |
| Mar 31, 2025 | -43.58 Mn |
| Mar 31, 2025 | -43.58 Mn |
| Dec 31, 2024 | 28.30 Mn |
| Dec 31, 2024 | 28.30 Mn |
| Sep 30, 2024 | -61.74 Mn |
| Sep 30, 2024 | -61.74 Mn |
| Jun 30, 2024 | -100.54 Mn |
| Jun 30, 2024 | -100.54 Mn |
| Mar 31, 2024 | 156.88 Mn |
| Mar 31, 2024 | 156.88 Mn |
| Dec 31, 2023 | 22.63 Mn |
| Dec 31, 2023 | 22.63 Mn |